Prescription medicine
Daraxonrasib Brand names: Rasonque
Daraxonrasib (Rasonque) is a prescription medicine with an FDA approval on record since 2026. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the daraxonrasib FDA label on DailyMed (effective August 27, 2026, Revolution Medicines, Inc.); the NDA 220910 record on Drugs@FDA; every daraxonrasib label on DailyMed.
Highlights of the record
FDA label of August 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageRASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Forms and strengths
- 100 mg
- 150 mg
Film-coated tablet.
On the market
- Earliest approval on file
- August 26, 2026 Rasonque, Revolution Medicines; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is daraxonrasib used for?
From the label: indications and usageRASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. RASONQUE is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Source: FDA drug label (RASONQUE), Revolution Medicines, Inc., effective August 27, 2026 (SPL set 13a65923-d072-4dac-8620-8eabbf8c3641), via openFDA; the full label on DailyMed
What does the patient leaflet for daraxonrasib say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about RASONQUE?RASONQUE can cause serious side effects, including: Skin reactions. Skin reactions may be severe. To help reduce your risk of skin reactions and protect your skin when starting and during treatment with RASONQUE: use a topical steroid cream on your face and chest use a moisturizing cream on your skin limit your time in the sun and use sunscreen (broad spectrum SPF 30 or higher) and other sun protection measures such as clothing and hats if you must be in the sun take any other medicines if prescribed by your healthcare provider Tell your healthcare provider right away if you develop any signs or symptoms of skin reactions, including: rash itching red, swollen, and painful skin around your finger or toenails dry skin cracked skin Swelling or sores in the mouth (stomatitis). Mouth sores may be severe. Your healthcare provider may prescribe a mouthwash or other medicines to treat your mouth reactions. Tell your healthcare provider right away if you develop trouble eating, talking, swallowing, or develop any new or worsening signs or symptoms in your mouth, including: pain redness swelling ulcers or sores Diarrhea. Diarrhea may be severe. If you develop diarrhea during treatment with RASONQUE, your healthcare provider may prescribe medicines to treat your diarrhea. Tell your healthcare provider right away if you develop new or worsening diarrhea or if the number of bowel movements you have in a day increases by 6 or more. See “ What are the possible side effects of RASONQUE? ” for more information about side effects.
From the patient leaflet: How should I store RASONQUE?Store RASONQUE at room temperature between 68°F to 77°F (20°C to 25°C). Keep RASONQUE and all medicines out of the reach of children.
Source: FDA drug label (RASONQUE), Revolution Medicines, Inc., effective August 27, 2026 (SPL set 13a65923-d072-4dac-8620-8eabbf8c3641), via openFDA; the full label on DailyMed
Is there a generic for daraxonrasib (Rasonque)?
No generic daraxonrasib is approved (Drugs@FDA, October 8, 2026).
- 2026 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the daraxonrasib label say about other medicines?
The daraxonrasib label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Chlorhexidine | warnings and precautions | Initiate a steroid-containing mouthwash for treatment of stomatitis and administer other topical treatments (e.g., chlorhexidine mouthwash, 2% lidocaine viscous) as clinically indicated. |
| Cyclosporine | drug interactions | Cyclosporine A Prevention or Management Avoid concomitant use of RASONQUE with systemic cyclosporine A or its derivatives. |
| Lidocaine | warnings and precautions | Initiate a steroid-containing mouthwash for treatment of stomatitis and administer other topical treatments (e.g., chlorhexidine mouthwash, 2% lidocaine viscous) as clinically indicated. |
Source: FDA drug label (RASONQUE), Revolution Medicines, Inc., effective August 27, 2026 (SPL set 13a65923-d072-4dac-8620-8eabbf8c3641), via openFDA; the full label on DailyMed
What next?
- Check an interaction
- what two or more labels say about each other